52 results about "Firmicutes" patented technology

Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia, and Akkermansia. Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by changing relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure.

The invention discloses cordyceps militaris intracellular polysaccharide and a preparation method thereof, and applications of the cordyceps militaris intracellular polysaccharide in regulation of intestinal flora. The method comprises the following steps: carrying out fermentation culture on cordyceps militaris strains, and separating to obtain cordyceps militaris mycelia; degreasing the cordyceps militaris mycelia, and performing hot water leaching to obtain a cordyceps militaris leaching liquid; and removing protein by adopting trypsin and a Sevage method, carrying out ethanol precipitation, and carrying out DEAE-Sepharose Fast Flow column chromatography purification to obtain the cordyceps militaris intracellular polysaccharide. The cordyceps militaris intracellular polysaccharide prepared by the invention can regulate the intestinal bacterial flora structure of a high-fat diet mouse, promote the growth of intestinal probiotics of high-fat diet mice, improve the proportion of phylum firmicutes / bacteroides, adjust the structure of fungal flora, promote the synthetic route of intestinal butyrate, induce activation of short-chain fatty acid receptors, promote fat metabolism and inhibit fat accumulation so as to achieve the effects of reducing blood fat and protecting the liver.

The invention discloses a bacillus toyonensis strain as well as a preparation method and application of a microbial agent thereof. The preservation department of the bacillus toyonensis SB3018 is China General Microbiological Culture Collection Center (CGMCC), the preservation date of the bacillus toyonensis SB3018 is November 21, 2014, the preservation number of the bacillus toyonensis SB3018 isCGMCC No. 10033; the bacillus toyonensis belongs to the realm of eubacteria, firmicutes, bacilli, bacillaceae and bacillus. The microbial agent of the bacillus toyonensis SB3018 is prepared by carrying out slant culture, seed culture and fermentation on the bacillus toyonensis SB3018. The preparation method comprises the steps of slant culture, seed culture, fermentation and microbial agent preparation; the microbial agent of the bacillus toyonensis SB3018 is applied to preparation of medicines for preventing and controlling tobacco root knot nematode disease and tobacco black shank. The preparation prepared by taking the bacillus toyonensis as an active component has a remarkable killing effect for the tobacco root knot nematode.

The invention relates to a special white shrimp breeding composite bacterium flora which comprises 9% of bdellovibrio BDS01, 4% of bdellovibrio BDS02, 5% of nitrobacterium, 3% of streptococcus thermophilus, 12% of yeast, 1.5% of lactobacillus bulgaricus, 1.5% of leuconostoc, 5% of aerobic denitrification bacteria, 0.5% of pediococcus, 5% of bacillus subtilis BDS-2, 2.5% of rhodobacter D8-35, 1% ofactinomycetes S317, 1% of a bacillus B135, 5% of yeast E7, 5% of acetobacterium balch, 5% of methane producing bacteria, 4% of lactic acid bacteria L2, 3% of aerobic spore-bearing bacilli, 2% of flavobacterium, 5% of bacillus coagulans, 3% of anaerobic lactobacillus, 1% of rhodop seudanonas palustris, 0.5% of pseudoalteromonas, 0.5% of rhodobacter azotoformans, 0.5% of firmicutes, 1% of lipoidase, 0.5% of protease, 1% of cyanobacteria, 3% of aerobic denitrification bacteria, 0.5% of actinomycetes, 0.2% of bacillus natto, 0.5% of viable bacteria of clostridium butyricum, 3% of photosynthetic bacteria and 0.8% of photosynthetic bacteria. Harmful indexes such as CODs (Chemical Oxygen Demands), ammonia nitrogen,nitrite and the like can be effectively controlled.

The present invention relates to monoclonal antibodies capable of recognising and binding to the PBP2-a protein and to other proteins having sequences homologous to PBP2-a, including pathogenic species such as the methyciline-resistant Staphylococcus Aureus (MRSA), coagulase-negative Staphilococcus, Staphylococcus sciuri and Enterococcus, and any other bacteria containing the PBP2-a protein or homologous sequences. The invention also relates to the use of the monoclonal antibodies capable of recognising and binding to the PBP2-a protein and to other proteins having sequenceshomologous to PBP2-a in a complementary immunodiagnostic test for detecting resistance to beta-lactam antibiotics.

The invention discloses a method for extracting undaria pinnatifida sulfated polysaccharide. The method includes utilizing undaria pinnatifida powder as a raw material and then conducting enzymatic hydrolysis, enzyme deactivation, sodium alginate removal, CTAB precipitation, dissolution, concentration and desalting and lyophilization to obtain the undaria pinnatifida sulfated polysaccharide. The extraction rate of the undaria pinnatifida sulfated polysaccharide is 0.45%-0.55%. Compared with the other methods, the method achieves the higher extraction rate, and the purity of the obtained undaria pinnatifida sulfated polysaccharide is better, being 86.42%-88.59%. The undaria pinnatifida sulfated polysaccharide can be used for regulating intestinal microorganisms, especially for improving theproportion of firmicutes and bacteroides in the intestinal tract.

The invention provides application of a mesona chinensis extract in preparation of drugs or health-care products for regulating intestinal flora and relates to the technical field of traditional Chinese medicines. According to the application, experiments prove that the mesona chinensis extract can be used for regulating an intestinal flora structure of a high-fat rat, promoting growth of beneficial bacteria, i.e., akkermansia muciniphila, improving a ratio of firmicutes / bacteroidetes, regulating the content of short-chain fatty acids, improving disorder of the intestinal florae, promoting metabolism of fats and inhibiting accumulation of the fats, thereby playing a role in reducing blood fat and protecting liver.

The invention provides a biogas fermentation promotion agent. The promotion agent is prepared from a following microorganism culture solution according to the volume part of the microorganism culturesolution, 15 to 20 parts of firmicutes, 15 to 20 parts of bacteroides, 3 to 5 parts of spirochaeta, 4 to 6 parts of thermotoga, 3 to 5 parts of deltaproteo bacteria, 3 to 5 parts of synergistetes, 3 to 5 parts of cellulomonas and 35 to 40 parts of euryarchaeota. According to the biogas fermentation promotion agent provided by the invention, selected 13 anaerobic fermentation functional strains arepreserved in strain preservation centers at home and abroad and are easy to obtain, culture and compound; according to the fermentation promotion agent provided by the invention, various microorganisms are matched reasonably and can be adaptive to fermentation raw materials with different types so that various raw materials can be rapidly degraded and converted into biogas; according to the biogas fermentation promotion agent, various microorganisms have the same or similar growth culture conditions and the promotion bacterium agent can normally grow and metabolize under the same environmentcondition and play the largest role.

The present invention provides a prophylactic or therapeutic composition for a metabolic disorder, a composition for amplifying the amount of short-chain fatty acid in the intestine, or a composition for decreasing a ratio of bacteria belonging to the Firmicutes to bacteria belonging to the Bacteroidetes in the intestine, each containing an exopolysaccharide produced by Leuconostoc mesenteroides, and further, a food, a pharmaceutical product, a feed and the like containing the composition.

The invention discloses a bacillus arzii and its preparation method and application, the bacillus arzii ( Bacillus aryabhattai ) BC104 is an efficient cypermethrin degrading bacterium, deposit unit: General Microbiology Center (CGMCC) of China Microbiological Culture Collection Management Committee (CGMCC), deposit date: December 15, 2015, deposit number: CGMCC No.11664; the Bacillus arborii belongs to Bacteria Kingdom, Firmicutes, Bacillus class, Bacillus order, Bacillus family, Bacillus genus. The bacterium that said bacillus arborii is an active ingredient is based on said bacillus arborii ( Bacillus aryabhattai ) BC104 is a bacterial agent made after activation culture and fermentation culture. The preparation method comprises the steps of activation culture and fermentation culture; the application of the bacterial agent in the preparation of drugs for degrading beta-cypermethrin. The bacterial agent of the bacterial strain of the invention has simple preparation process, low cost, convenient use and good application prospect.

The invention discloses a new application of sodium copper chlorophyllin, relates to the field of medicine, and relates to the application of sodium copper chlorophyllin in the preparation of medicines for treating and regulating intestinal flora. The beneficial effects of the present invention are: the sodium copper chlorophyllin is similar to prebiotics, which balances the microbial flora ecology of the intestinal tract, thereby limiting the growth of conditional pathogenic bacteria and the release of bacterial toxins in the intestinal tract, thereby alleviating liver disease. The present invention verifies through experiments that the sodium copper chlorophyllin can be used to regulate intestinal flora, increase the number of Firmicutes bacteria, and inhibit the abundance of α-proteobacteria and γ-proteobacteria. The imbalance of intestinal flora is closely related to various liver diseases, including liver failure and cirrhosis. Therefore, the preparation of sodium copper chlorophyllin can be used to prevent and treat various liver diseases.

The present invention relates to monoclonal antibodies capable of recognising and binding to the PBP2-a protein and to other proteins having sequences homologous to PBP2-a, including pathogenic species such as the methyciline-resistant (MRSA), coagulase-negative, and , and any other bacteria containing the PBP2-a protein or homologous sequences. The invention also relates to the use of the monoclonal antibodies capable of recognising and binding to the PBP2-a protein and to other proteins having sequences homologous to PBP2-a in a complementary immunodiagnostic test for detecting resistance to beta-lactam antibiotics.

The invention discloses the application of flavonoid glycosides of varicoseline in improving intestinal barrier function, and belongs to the technical field of drug development. In the present invention, the main active ingredient of blalicius seeds - the flavonoid glycosides of blalicius, is applied to improve intestinal barrier function. This natural substance can significantly improve the intestinal barrier function of animals, reduce the serum endotoxin content of mice with impaired barrier function, increase the intestinal alkaline phosphatase level and tight junction protein expression, and short-chain fatty acids in feces Propionic acid and butyric acid content, and can adjust the balance of intestinal flora, reduce the relative abundance of Firmicutes, and increase the relative abundance of Bacteroidetes and Proteobacteria.